Trial Profile
Phase II trial: uPAR-PET/CT for prognostication in head- and neck cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Gallium-68 NOTA AE105 (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Pharyngeal neoplasms
- Focus Diagnostic use
- 01 Nov 2022 Status changed from recruiting to completed.
- 11 Sep 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 11 Sep 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.